Literature DB >> 15120043

Modelling approaches for angiogenesis.

G Taraboletti1, R Giavazzi.   

Abstract

The development of a functional vasculature within a tumour is a requisite for its growth and progression. This fact has led to the design of therapies directed toward the tumour vasculature, aiming either to prevent the formation of new vessels (anti-angiogenic) or to damage existing vessels (vascular targeting). The development of agents with different mechanisms of action requires powerful preclinical models for the analysis and optimization of these therapies. This review concerns 'classical' assays of angiogenesis in vitro and in vivo, recent approaches to target identification (analysis of gene and protein expression), and the study of morphological and functional changes in the vasculature in vivo (imaging techniques). It mainly describes assays designed for anti-angiogenic compounds, indicating, where possible, their application to the study of vascular-targeting agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15120043     DOI: 10.1016/j.ejca.2004.01.002

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  18 in total

1.  CDP-diacylglycerol synthetase-controlled phosphoinositide availability limits VEGFA signaling and vascular morphogenesis.

Authors:  Weijun Pan; Van N Pham; Amber N Stratman; Daniel Castranova; Makoto Kamei; Kameha R Kidd; Brigid D Lo; Kenna M Shaw; Jesus Torres-Vazquez; Constantinos M Mikelis; J Silvio Gutkind; George E Davis; Brant M Weinstein
Journal:  Blood       Date:  2012-05-30       Impact factor: 22.113

2.  1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway.

Authors:  Xiufeng Pang; Li Zhang; Li Lai; Jing Chen; Yuanyuan Wu; Zhengfang Yi; Jian Zhang; Weijing Qu; Bharat B Aggarwal; Mingyao Liu
Journal:  Carcinogenesis       Date:  2011-03-22       Impact factor: 4.944

3.  Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.

Authors:  Ying-Ying Lu; Da-Dao Jing; Ming Xu; Kai Wu; Xing-Peng Wang
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

4.  Endothelial cells expressing low levels of CD143 (ACE) exhibit enhanced sprouting and potency in relieving tissue ischemia.

Authors:  Eduardo A Silva; Chikezie Eseonu; David J Mooney
Journal:  Angiogenesis       Date:  2014-01-11       Impact factor: 9.596

5.  Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice.

Authors:  L Li; Y-Z Yuan; J Lu; L Xia; Y Zhu; Y-P Zhang; M-M Qiao
Journal:  Gut       Date:  2005-11-15       Impact factor: 23.059

6.  5-Formylhonokiol exerts anti-angiogenesis activity via inactivating the ERK signaling pathway.

Authors:  Wei Zhu; Afu Fu; Jia Hu; Tianen Wang; Youfu Luo; Ming Peng; Yinghua Ma; Yuquan Wei; Lijuan Chen
Journal:  Exp Mol Med       Date:  2011-03-31       Impact factor: 8.718

7.  Synthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenes.

Authors:  Pascal Rouge; Alexandra Dassonville-Klimpt; Christine Cézard; Stéphanie Boudesocque; Roger Ourouda; Carole Amant; François Gaboriau; Isabelle Forfar; Jean Guillon; Emmanuel Guillon; Enguerran Vanquelef; Piotr Cieplak; François-Yves Dupradeau; Laurent Dupont; Pascal Sonnet
Journal:  Chempluschem       Date:  2012-11-01       Impact factor: 2.863

8.  Glioblastoma-dependent differentiation and angiogenic potential of human mesenchymal stem cells in vitro.

Authors:  Tobias Birnbaum; Jenna Hildebrandt; Georg Nuebling; Petra Sostak; Andreas Straube
Journal:  J Neurooncol       Date:  2011-03-11       Impact factor: 4.130

Review 9.  Following up tumour angiogenesis: from the basic laboratory to the clinic.

Authors:  José L Orgaz; Beatriz Martínez-Poveda; Nuria I Fernández-García; Benilde Jiménez
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

10.  Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA.

Authors:  Xiaoxia Liu; Wei Wang; Dmitry Samarsky; Li Liu; Qian Xu; Wenqing Zhang; Guangzu Zhu; Ping Wu; Xialin Zuo; Houliang Deng; Jingjing Zhang; Zhuomin Wu; Xiaohui Chen; Lingfeng Zhao; Zhiyong Qiu; Zhongyi Zhang; Qiyi Zeng; Wei Yang; Biliang Zhang; Aimin Ji
Journal:  Nucleic Acids Res       Date:  2014-09-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.